Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report

Aziza T. Shad, Jeffrey Huo, Courtney Darcy, Amal Abu-Ghosh, Giuseppe Esposito, Mary Jo Holuba, Nancy Robey, Kenneth R Cooke, Heather Symons, Allen R Chen, Nicolas Llosa

Research output: Contribution to journalArticle

Abstract

To date, there has been a lack of pediatric experience regarding the efficacy and tolerability of immune checkpoint inhibitors after haploidentical hematopoietic stem cell transplant (HSCT). We present the case of a 22-year-old female with multiple-relapsed Hodgkin lymphoma (HL) who presented with a new relapse after haploidentical (post-haplo) HSCT. Anti-PD-1 therapy with nivolumab resulted in significant objective disease response and clinical improvement without notable side effects, including the absence of a graft-versus-host disease (GVHD). This case report suggests that immune checkpoint inhibition may be safely tolerated even in the setting of haploidentical HSCT, without triggering overt GVHD.

Original languageEnglish (US)
JournalPediatric Blood and Cancer
DOIs
StateAccepted/In press - 2016

Keywords

  • Anti-PD1
  • Haploidentical bone marrow transplant
  • Hodgkin lymphoma
  • Immunotherapy
  • Nivolumab
  • Relapse

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report'. Together they form a unique fingerprint.

  • Cite this